Eastham James A, Scardino Peter T, Kattan Michael W
Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1. doi: 10.1016/j.juro.2008.01.106. Epub 2008 Apr 18.
The optimal outcome after radical prostatectomy for clinically localized prostate cancer is freedom from biochemical recurrence along with the recovery of continence and erectile function, a so-called trifecta. We evaluated our series of open radical prostatectomy cases to determine the likelihood of this outcome and develop a nomogram predicting the trifecta.
We reviewed the records of patients undergoing open radical prostatectomy for clinical stage T1c-T3a prostate cancer at our center during 2000 to 2006. Men were excluded if they received preoperative hormonal therapy, chemotherapy or radiation therapy, if pretreatment prostate specific antigen was more than 50 ng/ml, or if they were impotent or incontinent before radical prostatectomy. A total of 1,577 men were included in the study. Freedom from biochemical recurrence was defined as post-radical prostatectomy prostate specific antigen less than 0.2 ng/ml. Continence was defined as not having to wear any protective pads. Potency was defined as erection adequate for intercourse upon most attempts with or without phosphodiesterase-5 inhibitor.
Mean patient age was 58 years and mean pretreatment prostate specific antigen was 6.4 ng/ml. A trifecta outcome (cancer-free status with recovery of continence and potency) was achieved in 62% of patients. In a nomogram developed to predict the likelihood of the trifecta baseline prostate specific antigen was the major predictive factor. Area under the ROC curve for the nomogram was 0.773 and calibration appeared excellent.
A trifecta (optimal) outcome can be achieved in most men undergoing radical prostatectomy. The nomogram permits patients to estimate preoperatively their likelihood of an optimal outcome after radical prostatectomy.
临床局限性前列腺癌根治性前列腺切除术后的最佳结果是无生化复发,同时恢复控尿和勃起功能,即所谓的“三连胜”。我们评估了一系列开放性根治性前列腺切除术病例,以确定这一结果的可能性,并制定一个预测“三连胜”的列线图。
我们回顾了2000年至2006年在我们中心接受开放性根治性前列腺切除术治疗临床分期为T1c - T3a前列腺癌患者的记录。如果患者接受过术前激素治疗、化疗或放疗,术前前列腺特异性抗原超过50 ng/ml,或者在根治性前列腺切除术之前已阳痿或失禁,则将其排除。共有1577名男性纳入研究。无生化复发定义为根治性前列腺切除术后前列腺特异性抗原小于0.2 ng/ml。控尿定义为无需使用任何护垫。勃起功能定义为在大多数尝试性交时,无论是否使用磷酸二酯酶-5抑制剂,勃起状态足以进行性交。
患者平均年龄为58岁,术前平均前列腺特异性抗原为6.4 ng/ml。62%的患者实现了“三连胜”结果(无癌状态且控尿和勃起功能恢复)。在为预测“三连胜”可能性而制定的列线图中,基线前列腺特异性抗原是主要预测因素。该列线图的ROC曲线下面积为0.773,校准效果良好。
大多数接受根治性前列腺切除术的男性可以实现“三连胜”(最佳)结果。该列线图可让患者在术前评估其根治性前列腺切除术后获得最佳结果的可能性。